3.89
Cardiff Oncology Inc stock is traded at $3.89, with a volume of 999.12K.
It is down -5.43% in the last 24 hours and up +26.29% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$4.14
Open:
$4.15
24h Volume:
999.12K
Relative Volume:
0.86
Market Cap:
$259.45M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-4.1828
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
-8.53%
1M Performance:
+26.29%
6M Performance:
+14.81%
1Y Performance:
+65.54%
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CRDF
Cardiff Oncology Inc
|
3.90 | 285.40M | 488.00K | -41.44M | -31.47M | -0.93 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
467.67 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.06 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
327.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
592.49 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
292.01 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
Jun-24-25 | Initiated | Jefferies | Hold |
Sep-06-24 | Initiated | Craig Hallum | Buy |
Jan-05-22 | Initiated | William Blair | Outperform |
Dec-08-21 | Initiated | Robert W. Baird | Outperform |
Aug-09-21 | Resumed | Maxim Group | Buy |
Oct-22-20 | Initiated | H.C. Wainwright | Buy |
Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
What analysts say about Cardiff Oncology Inc. stockExplosive capital appreciation - Autocar Professional
Is Cardiff Oncology Inc. a good long term investmentRapidly expanding wealth - Autocar Professional
Cardiff Oncology Inc. Stock Analysis and ForecastExplosive trading opportunities - Autocar Professional
What drives Cardiff Oncology Inc. stock priceFast-track wealth growth - jammulinksnews.com
What makes Cardiff Oncology Inc. stock price move sharplyFree Day Trading Recommendations - Newser
Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term (NASDAQ:CRDF) - Seeking Alpha
How Cardiff Oncology Inc. stock performs during market volatilityHigh Return Setup Scanner - Newser
Why Cardiff Oncology Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co. - The Globe and Mail
Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World
Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World
Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN
Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com Canada
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - GlobeNewswire
International Business Times - FinancialContent
Cardiff Oncology Up 16%, Insider Buyers Are Up 35% - simplywall.st
While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the most - Yahoo Finance
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
Cardiff Oncology Holds Annual Stockholders Meeting 2025 - TipRanks
Jefferies Initiates Coverage on Cardiff Oncology (CRDF) with Hol - GuruFocus
Cardiff Oncology (CRDF) Begins Coverage With Hold Rating from Jefferies | CRDF Stock News - GuruFocus
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga
Cardiff Oncology stock initiated at Hold by Jefferies on early data concerns - Investing.com
Market Overreaction to Cardiff Oncology's Data Delay Presents a Rare Buying Opportunity - AInvest
Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus
Cardiff Oncology falls after naming new medical chief ahead of key trial readout - MSN
CRDF Set to Release Key Clinical Data Amid Leadership Changes | CRDF Stock News - GuruFocus
Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer By Investing.com - Investing.com India
Cardiff Oncology (CRDF) Welcomes New Chief Medical Officer | CRD - GuruFocus
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Offic - GuruFocus
Cardiff Oncology (CRDF) Shares Drop 11% After Leadership Change - GuruFocus
Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer - MarketScreener
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):